Treatment of attention deficit hyperactivity disorder in adults and children. Maintenance treatment of ADHD in adults 18–55yrs of age.
<6yrs: not recommended. Individualize. ≥6yrs: 30mg once daily in AM. May increase at 1-week intervals by 10mg or 20mg per day; max 70mg/day. May dissolve contents of capsule in water, take immediately (do not subdivide caps).
Advanced arteriosclerosis. Symptomatic cardiovascular disease. Moderate to severe hypertension. Hyperthyroidism. Glaucoma. Agitation. Drug abusers. Hypersensitivity or idiosyncrasy to sympathomimetics. Within 14 days of MAOIs.
Increased risk of sudden death or other serious cardiovascular events. Pre-existing structural cardiac abnormalities. Hypertension. Heart failure. Recent MI. Arrythmias. Bipolar disorder. Psychoses. Tourette's syndrome. Tics. Discontinue if seizures occur. Drug abusers. Impaired renal, hepatic, or thyroid function. Reevaluate periodically. Monitor growth, BP, heart rate, worsening aggressive behavior or hostility. Write ℞ for smallest practical amount. Pregnancy (Cat.C). Nursing mothers: not recommended.
See Contraindications. Hypertensive crisis with MAOIs, furazolidone. Potentiated by tricyclics, propoxyphene, urinary alkalinizing agents. Potentiates meperidine, norepinephrine, phenobarbital, phenytoin, tricyclics. Antagonized by urinary acidifiers, methenamine therapy, psychotropics (eg, haloperidol, chlorpromazine), lithium. Antagonizes adrenergic blockers, antihistamines, veratrum alkaloids, ethosuximide, antihypertensives. Monitor phenytoin, ethosuximide, phenobarbital. Convulsions with propoxyphene overdose. Caution with other sympathomimetics. May interfere with urinary steroid tests.
Decreased appetite/weight, dry mouth, irritability, insomnia, jitteriness, dizziness, headache, anxiety, fatigue, upper abdominal pain, GI upset; hypertension, blurred vision, psychosis, tics, rash (may be serious).